Search Results
Your search for ,WHo matches 20420 pages
Showing 5951 - 6000Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression
On February 22, 2021, cemiplimab-rwlc was approved for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC; locally advanced who are not candidates for surgical resection or definitive chemoradiation therapy or metastatic) whose tumors have high PD-L1 expression (tumor...
Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic
Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...
Comparing Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage III to IV Melanoma
The addition of ipilimumab to nivolumab failed to improve outcomes compared with nivolumab alone as adjuvant therapy for resected melanoma, according to the results of the CheckMate 915 trial, presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting...
Expert Point of View: Peter Martin, MD
“With current therapies, the median survival for people with follicular lymphoma [FL] is about 20 years. Most people with FL will live as long as the general population, as it is a disease of morbidity more than mortality. That said, there is still room for improvement,” said formal CHRONOS-3...
CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free Survival in Relapsed Indolent NHL
The combination of the PI3K inhibitor copanlisib plus the monoclonal antibody rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL), according to the results of the phase III CHRONOS-3...
City of Hope Renames Research Center as the Arthur Riggs Diabetes & Metabolism Research Institute
City of Hope has announced the renaming of its diabetes research center as the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its long-time director and research pioneer. Arthur Riggs, PhD, is known for scientific achievements that include developing the technology leading...
A Sense of Duty Shapes the Career of Medical Oncologist Aparna Parikh, MD
By way of her family lineage, Aparna Parikh, MD, seemed destined for a career in medicine. “Both of my parents are physicians, as well as my maternal grandfather. I have two other siblings, all of whom are in the medical field. Medicine has always been part of my life since childhood. My parents...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
Tebentafusp Shows Overall Survival Benefit in First-Line Treatment of Metastatic Uveal Melanoma
Treatment with tebentafusp—a novel bispecific fusion protein—reduced the risk of death from metastatic uveal melanoma by half, compared with available treatments, in a phase III study presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.1 This is the first...
Expert Point of View: Ursula Matulonis, MD, and Konstantin Zakashansky, MD
Perspectives on ARIEL4 were provided for The ASCO Post by the invited discussant Ursula Matulonis, MD, Professor of Medicine, Harvard Medical School, and Chief of Gynecologic Oncology and the Brock Wilson Family Chair at Dana-Farber Cancer Institute, Boston, and by Konstantin Zakashansky, MD,...
Phase III ARIEL4 Confirms Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer
In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP (poly [ADP-ribose] polymerase) inhibitor rucaparib led to a significant improvement in progression-free survival compared with standard-of-care chemotherapy, according to results of the international phase III ...
Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize several different types of head and neck diseases, primarily those that are human ...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC
Neoadjuvant chemotherapy with nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to the results of the CheckMate 816 study...
Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology
Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...
Are Prevalent Cardiovascular Risk Factors Associated With Increased Risk of Subsequent Cancer?
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, of the Cardiology Division, Department of Medicine, Massachusetts General Hospital, and colleagues found that the presence of cardiovascular disease (CVD) risk factors was significantly associated with an increased risk of future...
Virtual Meetings Are Here to Stay
In 2020, the 8th Annual Beirut Breast Cancer Conference (BBCC) was our last in-person meeting. The first cases of COVID-19 started in Lebanon around the end of February 2020, and the pandemic continues into its second year, with waves of rising cases following superspreader events and other likely...
Chênevert Family Brain Tumor Center Launched at Yale
Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...
Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality
Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...
Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden
Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for patients with cancer, these issues were particularly acute, likely due to isolation and social distancing, according to a recent study published by Miaskowski et al in the ...
Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve
In a study reported in the Journal of Clinical Oncology, Turan et al found the presence of germline BRCA pathogenic variants was associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and those with BRCA1 variants. Study Details The individual...
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity
In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and...
Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race
A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...
IMagyn050 Trial: Addition of Atezolizumab to Bevacizumab and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer
As reported in the Journal of Clinical Oncology by Kathleen N. Moore, MD, and colleagues, the phase III IMagyn050/GOG 3015/ENGOT-OV39 trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve progression-free survival in patients with newly...
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer
On May 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
Accuracy of Lung Cancer Risk Model in Diverse Populations
A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...
Oncologists’ Views on Challenges in Opioid Prescribing for Patients With Cancer-Related Pain
In an interview study reported in JCO Oncology Practice, Yael Schenker, MD, MAS, and colleagues identified challenges and measures for improvement cited by oncologists in the safe and effective prescribing of opioids for their patients with cancer-related pain. Study Details The investigators...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
Risk of Colorectal Cancer and Colorectal Polyps in First-Degree Family Members
Researchers have demonstrated a possible connection between colorectal polyps in close relatives and the risk of developing colorectal cancer. The study, which was published by Song et al in the British Medical Journal, is of potential consequence for cancer screening procedures. Colorectal cancer...
One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy
In an interim analysis of a prospective observational study reported in The Lancet Oncology, Monin et al found that a single dose of the BNT162b2 Pfizer–BioNTech COVID-19 vaccine was poorly immunogenic in patients with cancer, with immunogenicity markedly improving at 2 weeks after a second dose...
Variations in Testing and Treatment Across Medical Specialties for Men Initiating Active Surveillance for Prostate Cancer
In a study reported in JCO Oncology Practice, Lai et al found that although the majority of men who have initiated active surveillance for prostate cancer are followed by urologists, some are managed by physicians in other specialties, and that testing and subsequent treatment patterns vary across...
Ten-Year Outcomes With Neoadjuvant Chemoradiotherapy Plus Surgery vs Surgery Alone for Esophageal Cancer
As reported in the Journal of Clinical Oncology by Eyck et al, 10-year follow-up of the Dutch CROSS trial has shown a continued overall survival benefit with neoadjuvant chemoradiotherapy plus surgery vs surgery alone in patients with locally advanced resectable esophageal or gastroesophageal...
FDA Pipeline: Priority Reviews of Treatments for Bladder and Lung Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review designation to treatments for surgically resected, high-risk, muscle-invasive urothelial carcinoma and epidermal growth factor receptor exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC)....
Heritability Genes Identified in Childhood Neuroblastoma
Researchers have made progress in unravelling the genetic underpinnings of pediatric neuroblastoma. Two main inherited pathogenic genetic variants have been identified and appear to be associated with worse outcomes: the ALK gene and loss of function in PHOX2B. The research, conducted with the...
First-Line Immune Checkpoint Inhibitor Monotherapy vs Chemoimmunotherapy in Advanced NSCLC According to KRAS Variant Status
In a study reported in a research letter in JAMA Oncology, Sun et al found that first-line immune checkpoint inhibitor monotherapy was associated with better overall survival among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% and KRAS variant vs KRAS...
More From the FDA ODAC: Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer
More news has emerged from this week’s meeting of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). The group voted 8 to 0 in favor of continuing the accelerated approval for pembrolizumab in sorafenib-pretreated patients with hepatocellular carcinoma; 6 to 2...
Five-Year Efficacy Outcomes With Pembrolizumab vs Chemotherapy in Metastatic NSCLC With PD-L1 Tumor Proportion Score of at Least 50%
As reported by Martin Reck, MD, PhD, and colleagues in the Journal of Clinical Oncology, the 5-year follow-up of the pivotal phase III KEYNOTE-024 trial shows maintained overall survival benefit in patients treated with pembrolizumab vs chemotherapy—despite substantial crossover to the...
Fertility Concerns May Influence Decisions About Endocrine Therapy in Young Women With Breast Cancer
Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, according to findings from a recent study published by Sella et al in the journal Cancer. The findings reinforce the need for...
FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments
Roche has announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining the accelerated approval of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for...
Breast Reconstruction Disparities Improved With Medicaid Expansion
Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction among non-Hispanic Black women, achieving parity at times with non-Hispanic White women, according to a new study presented by Sharon Lum, MD, and colleagues at the American Society...
Low-Risk Breast Cancer Survivors May Experience Long-Term Physical and Psychological Effects
Survivors of low-risk breast cancer may experience wide-ranging and significant physical and psychological symptoms after cancer treatment, according to a new study presented by Jessica Schumacher, PhD, and colleagues at the American Society of Breast Surgeons (ASBrS) Annual Meeting. Researchers...
COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization
The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...
Patient-Centered Outcomes in the SOLO-1 Trial of Maintenance Olaparib for Advanced Ovarian Cancer
In an analysis of health-related quality of life and patient-centered outcomes in the phase III SOLO-1 trial reported in The Lancet Oncology, Friedlander et al found no clinically meaningful difference in health-related quality of life—and improved quality-adjusted progression-free survival and...
Daratumumab in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Results from the single-institution phase II MANHATTAN study were reported in JAMA Oncology recently by Ola Landgren, MD, PhD, and colleagues. The investigators found that daratumumab in combination with weekly carfilzomib, lenalidomide, and dexamethasone resulted in high rates of minimal residual...
Sacituzumab Govitecan-hziy Improves Survival vs Single-Agent Chemotherapy in Metastatic Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Aditya Bardia, MD, of the Division of Medical Oncology, Massachusetts General Hospital Cancer Center, and colleagues, the phase III ASCENT trial has shown prolonged progression-free and overall survival with the Trop-2–directed antibody-drug...
YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content
Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...
New Research Finds Few Young Adult Men Have Received the HPV Vaccine
Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...
Platinum-Sensitive Recurrent Ovarian Cancer
Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss a case of a woman with platinum-sensitive recurrent ovarian cancer who was found to have a germline BRCA1 mutation. They address the question of how to choose the optimal chemotherapy regimen for patients who are...
Hormonal Intrauterine Device Under Study for Managing Early Endometrial Cancer
Disease regression was observed in 82% of women with endometrial hyperplasia with atypia and 43% of women with endometrial cancer after treatment for 6 months with a hormonal intrauterine device in a phase II study reported during the virtual edition of the Society of Gynecologic Oncology (SGO)...
Chernobyl at 35 Years: An Oncologist’s Perspective
Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...
